Investor Presentaiton

DSA Growth Drivers: Best-in-Class Science and Service Driving Sustained Demand Focused on preclinical R&D support ◉ ◉ - - M&A and technology partnerships enhancing scale, innovative capabilities, and therapeutic area expertise Sustained demand driven by greater outsourcing by biopharma clients Opportunity to drive incremental outsourcing penetration, with Discovery only ~30% outsourced and Safety Assessment 60%+ outsourced Biotech leveraging outsourcing expertise to drive innovation instead of building in-house capabilities Large biopharma utilizing scientific partners like CRL in place of maintaining internal resources Significant opportunity to further increase synergies and client overlap More than half of Discovery clients remained with CRL for safety assessment Digital transformation remains critical driver for sustained growth Successful launch of Apollo TM for Safety Assessment further connects clients to real-time data and our comprehensive portfolio Charles River Laboratories (CRL) 11

View entire presentation